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Molecular mechanisms of Charcot-
Marie-Tooth neuropathy linked  
to mutations in human myelin 
protein P2
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Erik I. Hallin3, Arne Raasakka3, Päivi Joensuu5, Ulrich Bergmann1,6, Ilpo Vattulainen2,7 &  
Petri Kursula  1,3
Charcot-Marie-Tooth (CMT) disease is one of the most common inherited neuropathies. Recently, 
three CMT1-associated point mutations (I43N, T51P, and I52T) were discovered in the abundant 
peripheral myelin protein P2. These mutations trigger abnormal myelin structure, leading to reduced 
nerve conduction velocity, muscle weakness, and distal limb atrophy. P2 is a myelin-specific protein 
expressed by Schwann cells that binds to fatty acids and membranes, contributing to peripheral 
myelin lipid homeostasis. We studied the molecular basis of the P2 patient mutations. None of the 
CMT1-associated mutations alter the overall folding of P2 in the crystal state. P2 disease variants show 
increased aggregation tendency and remarkably reduced stability, T51P being most severe. In addition, 
P2 disease mutations affect protein dynamics. Both fatty acid binding by P2 and the kinetics of its 
membrane interactions are affected by the mutations. Experiments and simulations suggest opening 
of the β barrel in T51P, possibly representing a general mechanism in fatty acid-binding proteins. Our 
findings demonstrate that altered biophysical properties and functional dynamics of P2 may cause 
myelin defects in CMT1 patients. At the molecular level, a few malformed hydrogen bonds lead to 
structural instability and misregulation of conformational changes related to ligand exchange and 
membrane binding.
A multilamellar membrane structure, myelin, enwraps selected axons in the nervous system, enabling the prompt 
transmission of nerve impulses along the axonal membrane. Myelin contains a compact lipid-rich compartment 
with a unique set of membrane-associated proteins, such as myelin protein zero (MPZ), peripheral myelin protein 
of 22 kDa (PMP22), myelin basic protein (MBP), and myelin protein P2, and more loosely packed regions that 
also encompass cytoplasm. Close interplay between myelin proteins is important for the formation of cytoplasmic 
channels within myelin1. In the peripheral nervous system (PNS), Schwann cells envelop axons and form insulat-
ing myelin sheaths. Defects in this fundamental structure result in chronic, severe neuropathological conditions, 
affecting nerve conduction velocity and neuron viability.
Charcot-Marie-Tooth disease (CMT) is one of the most common inherited human neuropathies (prevalence 
of 1:2500), affecting both motor and sensory nerve conduction in the PNS2. Several types of CMT exist; the most 
common form, autosomal dominant CMT1, influences Schwann cells and myelin. In CMT1, motor and sensory 
nerve conduction velocities are remarkably reduced, leading to muscle weakness and atrophy in the feet and occa-
sionally also in upper limbs. Demyelination and onion bulb formation are present in most CMT1 patients. Most 
commonly, CMT1a is caused by a duplication of or a point mutation in the pmp22 gene, and 70–80% of all CMT1 
cases are associated with pmp22 mutations3. CMT1b results from mutations in the mpz gene and comprises 4% of 
all CMT1 cases. A number of other CMT1-associated genes have been described2. Recently, three point mutations 
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in the pmp2 gene, coding for the myelin P2 protein, were linked to autosomal dominant CMT1. The I43N muta-
tion was discovered in two families4,5 and T51P and I52T each in one family6. All patients with these mutations 
have reduced motor and sensory nerve conduction velocities, thinner myelin sheaths, and demyelinating axons 
with onion bulb formation. Symptoms also include progressive hand and foot muscle weakness and atrophy, as 
well as foot deformity and sensory loss in limbs4–6. Although the pathological features of different CMT1 types 
are comparable, the molecular pathomechanisms are different7.
P2 is mainly expressed by Schwann cells in the PNS8. It is located in compact myelin, stabilizing the multilay-
ered lipid membrane assembly. P2 is a small 15-kDa protein with a β barrel structure covered by an α-helical lid9,10. 
It belongs to the conserved family of fatty acid-binding proteins (FABPs) and can transfer fatty acids from and 
to lipid membranes using a collision transfer mechanism, indicating a functional role in the lipid homeostasis of 
myelin11. P2 may also bind cholesterol; a CRAC cholesterol binding motif is found at its C terminus9,12.
Here, we show that the crystal structures of CMT1-associated P2 mutant forms remain nearly unaltered, but 
the stability of the mutant proteins is remarkably reduced. Mutant proteins show decreased solubility, T51P trig-
gering the most significant effect. T51P has a reduced membrane stacking activity, while I43N and I52T maintain 
their ability to bind and stack lipid membranes. On the other hand, protein dynamics, as well as fatty acid and 
membrane binding kinetics, of all P2 mutants differ from those of wild-type P2 (P2wt). The mutations may cause 
defects in protein folding and the regulation of functional conformational changes, and they provide clues into 
ligand binding dynamics in the FABP family.
Results
In order to explore the functional and structural effects of CMT1-linked mutations in P2, we expressed and puri-
fied all three mutant proteins; I43N, T51P, and I52T. We used a range of experimental techniques together with 
atomistic simulations to study the effects of the mutations on P2 structure, function, and dynamics.
CMT mutations increase P2 aggregation but do not affect the overall crystal structure. In a prokaryotic 
expression system, all mutants showed a higher tendency to form insoluble aggregates than P2wt (Fig. 1A). Only 
~5% of T51P was soluble, despite optimised cell lysis conditions. Also both I43N and I52T showed reduced 
solubility compared to P2wt. However, soluble forms of all mutants could be purified and eluted as a single 
monomeric peak in size exclusion chromatography (SEC). We used dynamic light scattering (DLS) to further 
investigate the aggregation tendency of P2. P2wt, I43N, and I52T remained 100% monomeric for 24 h after SEC, 
while T51P was 98.3% monomeric, and high-molecular-weight forms were already present (Fig. 1B). The hydro-
dynamic radius (Rh) of monomeric T51P was also larger compared to the other variants (Table 1).
Small-angle X-ray scattering (SAXS) data were collected to monitor possible variation in the solution struc-
tures of the patient mutants (Fig. 1C). Scattering patterns of all mutants resemble those of P2wt. Nevertheless, 
the radius of gyration (Rg) and maximum dimension (Dmax) of I43N and T51P slightly deviate from P2wt, while 
I52T gave similar results (Table 1). The shape of the distance distribution function (Fig. 1D) differs between the 
variants, T51P and I52T being most divergent. This could be related to the position of the α-helical lid, the overall 
structure of the β barrel, and/or the level of saturation with fatty acid inside the barrel.
To address structural consequences of the mutations, we determined the respective crystal structures at high 
resolution (Table 2). All mutated residues are well defined in electron density. The mutations are located in the 
middle of the strands β2 and β3, in close proximity to the core of the β barrel (Fig. 1E,F). However, the overall 
fold of the structures is nearly identical to P2wt, with RMS deviations of 0.1–0.2 Å (Cα atoms). Considering the 
differences in solution conformations, this is a reflection of the selection of a single low-energy conformer into 
the crystal lattice, closely resembling the wild-type crystal structure. All structures present a gap in the β barrel 
between the strands β4 and β5, with no hydrogen bonds formed between the strands. This is a common feature 
of the FABP family13–17, and it is noteworthy that all the CMT1-linked P2 mutations lie close in space to this gap 
(Fig. 1E). The largest difference is triggered by the T51P mutation, which decreases the area of the β sheet β1–4 
(Fig. 1G). The mutation hinders the carbonyl group of Ile50 from forming a hydrogen bond with the amino 
group of Phe65 in the β4 strand; Pro51 also cannot form a hydrogen bond to Ser44 in the strand β2 (Fig. 1H). 
Two water molecules in close proximity to the residue 51 and the β2 and β3 strands are not found in the crystal 
structure of T51P, but they exist in all other structures. I43N and I52T do not alter the main chain conformation, 
and neither side chain generates steric clashes. These changes from a non-polar to a polar residue do not induce 
large structural changes in the crystal structure. However, the amino group of the Asn43 side chain of I43N forms 
an extra hydrogen bond to the main chain carbonyl group of Phe5, located at the end of the short α helix at the 
N terminus of P2.
Mutated forms of P2 have reduced stability. Due to increased aggregation tendency, the folding of the 
P2 variants was examined using synchrotron radiation circular dichroism spectroscopy (SRCD). Spectra were 
recorded in water and in phosphate buffer (Fig. 2A). The intensity of both the positive (at 198 nm) and negative 
(at 218 nm) peaks varied, P2wt giving the highest and T51P the lowest signal, suggesting formation of soluble 
aggregates of the mutant proteins. Minor variations were also observed in the shape and x axis intersections of the 
spectra, mainly for T51P, indicative of lower secondary structure content or altered conformation.
In the presence of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC): 1,2-dimyristoyl-sn-glycero-
3-(phospho-rac-(1-glycerol)) (DMPG) or 1,2-dioleyl-sn-glycero-3-phosphocholine (DOPC): 1,2-dioleyl- 
sn-glycero-3-phosphatidyl-rac-glycerol (DOPG) vesicles, the spectra of P2 clearly changed (Fig. 2A). This phe-
nomenon is more pronounced in water (Fig. 2A, right), where competition between lipid head groups and phos-
phate does not exist. In phosphate buffer (Fig. 2A, left), the positive peak at 198 nm decreased with P2wt and I52T, 
while I43N and T51P show opposite behavior. In water, the shape of the P2wt, I43N, and I52T spectra change 
considerably upon adding lipid vesicles, especially when DOPC:DOPG vesicles are introduced.
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Figure 1. Structure and stability of P2. (A) Solubility analysis. (B) Dynamic light scattering indicates 
aggregation of T51P. Note that the curves for P2wt and I43N nearly overlap in panels B and D. (C) The SAXS 
scattering curve. (D) Distance distribution functions. (E) Crystal structure of P2 with the mutant positions 
labelled. The bound fatty acid is shown in orange and the anion binding site with a chloride ion (green). (F) The 
mutation hot spot viewed from the bottom. (G) The crystal structure of T51P. Note the decreased area of the 
β sheet close to the mutation; compare the circled area with the corresponding area in panel E. (H) Hydrogen 
bonds near residue 51 in wild-type (green) and T51P (pink); the shown region corresponds to the circled area 
in panel G. Three hydrogen bonds are labeled: 1) main-chain H bond that is lost in the mutant protein, 2) side-
chain hydrogen bond lost in the mutant protein, 3) main-chain H bond that is in an unfavorable conformation 
in the mutant protein (orange).
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We further studied the thermal stability of P2 mutants using conventional CD spectroscopy (Fig. 2B). Tm 
analysis and CD spectra illustrate a drastic reduction of the stability of all patient mutants compared to P2wt 
(Tm = +65 °C); T51P has the lowest Tm, +41 °C, and already at +38 °C, the conformation of T51P changed 
and unfolding started. I43N has a Tm at +48 °C and I52T at +52 °C. Therefore, both of these mutants also have 
decreased thermal stability compared to P2wt.
Patient mutations modify the dynamics of all P2 mutants. Root mean square fluctuation (RMSF) 
analysis from atomistic molecular dynamics (MD) simulations was used to examine P2 dynamics with and with-
out bound palmitate inside the β barrel. Palmitate-bound P2wt is generally more dynamic than its empty counter-
part. The most mobile parts of P2wt are located in the loops and, to some extent, in the helical lid (Fig. 3A); these 
segments correspond to the portal region of FABPs. Similar behaviour was seen with palmitate-bound I43N. In 
MD simulations, palmitate-bound T51P is overall much more dynamic than the other P2 variants and shows 
strong fluctuations in the lid region as well as in the β sheets β2-5 and the loops connecting them. The lid region 
and the β3-β4 loop of I52T also fluctuate more heavily than those of P2wt. However, when the fluctuations of 
ligand-free P2 are compared, P2wt seems to be the least dynamic variant. I52T shows some fluctuations at certain 
parts, while I43N and T51P are rather rigid. Surprisingly, T51P is the least dynamic of the apo forms (Fig. 3A). 
The apo form of T51P is overall less dynamic than palmitate-bound T51P. The lid region of I52T and the β5-β6 
loop of I43N are also destabilised by palmitate, while other parts of the mutants show reduced fluctuation upon 
palmitate binding.
In simulations of P2, especially in the case of apo T51P, opening of the β barrel at the gap is observed (Fig. 3B). 
The hinge for this movement lies at Gly68 in the β4-β5 loop, which is one of the two absolutely conserved Gly 
residues across all human FABPs10. At the hinge also lies a buried water molecule, which is conserved in FABPs 
and was suggested to be relevant for correct folding18. It is possible that the conserved Gly residues and the water 
molecule also play roles in functional conformational changes in FABPs, including P2. Rg for all eight systems 
(four P2 forms, +/−palmitate) was estimated based on the MD simulations. The obtained values (Table 1) are 
in good agreement with those derived from SAXS. Ab initio modeling of T51P based on the SAXS data provides 
Protein
DLS SAXS MD simulations









wt 2.11 100 1.45 3.9 14 1.45 1.44
I43N 2.18 100 1.55 4.0 18 1.43 1.44
T51P 2.40 98.3 1.56 4.2 13 1.50 1.45
I52T 2.22 100 1.45 3.9 12 1.43 1.45
Table 1. DLS, SAXS, and MD simulation parameters.
Mutant I43N T51P I52T
Data collection
Beamline I04/Diamond I03/Diamond I04/Diamond
X-ray wavelength (Å) 0.9795 0.9762 0.9795
Space group P41212 P41212 P41212
Unit cell dimensions a, b, c (Å) 65.0,65.0,101.1 66.0,66.0,100.9 64.8,64.8,101.1
α, β, γ (°) 90,90,90 90,90,90 90,90,90
Resolution range (Å) 46–1.59 (1.69–1.59) 46–1.72 (1.87–1.72) 46–1.53 (1.63–1.53)
No. unique reflections 29518 (2710) 44944 (7154) 33053 (3233)
Completeness (%) 98.7 (89.2) 99.6 (97.5) 99.6 (99.6)
Redundancy 6.6 (6.4) 6.1 (6.1) 6.0 (5.9)
Rsym (%) 6.7 (300) 7.4 (267) 5.1 (265)
Rmeas (%) 7.0 (327) 8.1 (292) 5.3 (257)
<I/σI> 18.4 (0.7) 12.8 (0.8) 22.0 (0.7)
CC1/2 (%) 100 (73.4) 99.9 (67.8) 100 (72.8)
Wilson B (Å2) 29.3 31.2 29.2
Structure refinement
Rcryst/Rfree (%) 18.4/21.4 16.9/19.1 17.0/20.1
RMSD bond lengths (Å) 0.007 0.006 0.007
RMSD bond angles (°) 1.0 1.0 1.1
Molprobity score 1.24 1.57 1.97
Ramachandran favoured/ 
outliers (%) 100/0 98.7/0 100/0
Table 2. Crystallographic data collection and structure refinement.
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a shape very similar to that observed in the MD simulation (Fig. 3C), confirming the presence of an open, more 
extended conformation, of P2 in solution. In addition, multicomponent analysis of the SAXS data indicates a 7% 
fraction of open conformation of T51P in solution, while the other P2 forms exist in the closed conformation.
We also calculated the number of water molecules inside the P2 barrel during each simulation. The average 
number of water molecules inside unliganded P2 was 27.7, 30.5, 23.7, and 30.4 (for P2wt, I43N, T51P and I52T, 
respectively). For palmitate-bound P2 forms, the respective numbers of water molecules were 21.0, 22.1, 29.1, 
and 22.0. In both cases, T51P differs from the other variants, interestingly having less water molecules within 
the β barrel without than with palmitate inside. Here, the behaviour of the Ile mutants resemble each other but 
slightly differ from P2wt. These values are in accordance with studies on FABP, whereby faster exchange of water 
was observed for liganded FABP than for apo-FABP19 - a major route for water flow between bulk solvent and the 
internal cavity was suggested to be the gap between the strands β4 and β5. Both the apparent lower water content 
of apo T51P as well as its low RMSF during the MD simulation can be explained by the observation that the unli-
ganded T51P structure opens up early in the simulation and remains in the open conformation.
Fatty acid binding in P2 CMT mutants. P2 belongs to the family of FABPs, and in all crystal structures 
of human P2, there is a fatty acid inside the β barrel9,10,20,21. Also in the crystal structures of all mutant proteins 
studied here, a fatty acid, modelled as palmitate, is visible inside the β barrel. P2 captures abundant fatty acids 
during expression in E. coli9,10. With our earlier atomic-resolution crystallographic data, we modelled the fatty 
acid component as a mixture of palmitate and cis-vaccenate10.
Figure 2. SRCD analysis of P2 folding and membrane interactions. (A) Left: SRCD in phosphate buffer 
with and without DMPC:DMPG vesicles. Right: SRCD in H2O and with DMPC:DMPG (dashed lines) and 
DOPC:DOPG (dotted lines) vesicles. (B) Temperature scans of all variants. Temperatures between +40–50 °C 
are shown in red for clarity.
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To study fatty acid binding, we performed end-point binding assays with a fluorescent fatty acid derivative 
probe, 11-dansylaminoundecanoid acid (DAUDA)22. The peak maxima clearly increase and shift in the pres-
ence of P2, indicating an interaction involving a non-polar environment between DAUDA and all P2 variants 
(Fig. 3D). This phenomenon is most pronounced with T51P, but also I43N and I52T show higher fluorescence 
than P2wt. In this experimental setup, T51P seems to bind to DAUDA more effectively than the other mutants or 
P2wt, which might be related to its higher tendency to open.
Since the structure and dimensions of DAUDA diverge from natural fatty acids, we used liquid 
chromatography-mass spectrometry (LC-MS) to investigate the fatty acids bound to P2. Fatty acids with 16–20 
carbons without or with a double bond were monitored. The total amount of bound fatty acids was similar 
between all the P2 variants, and C16 and C18 fatty acids together comprise nearly 100% of the total fatty acid con-
tent. We compared the amount of saturated and non-saturated C16 and C18 fatty acids, and noted the fatty acid 
content of all variants was nearly identical (Fig. 3E). P2 contains more C18 (60–70%) than C16 fatty acids (30–
40%). Palmitate is the preferred C16 ligand, while for C18, nearly equal amounts of saturated and non-saturated 
fatty acid are observed. The result validates our high-resolution model10, in which we earlier built in palmitate 
(C16:0) and cis-vaccenate (C18:1) with partial occupancies.
P2 binding to immobilised lipid vesicles. The binding of P2 onto lipid membrane surfaces was studied 
using surface plasmon resonance (SPR) with two different lipid compositions, differing only in the identity of 
the hydrocarbon chains of the lipids (Fig. 4). SPR was not carried out with the T51P mutant due to its tendency 
Figure 3. Dynamics, open conformation, and fatty acid binding. (A) RMS fluctuation of apo (top) and liganded 
(bottom) forms. Above the graphs, the secondary structure elements of P2 are shown (black, strand; orange, 
helix). (B) Structure of P2wt (light brown) superimposed on the open conformation of T51P seen in simulations 
(blue). The two conserved FABP Gly residues in the β2-β3 and β4-β5 loops are shown in magenta, the positions 
of the mutations in green, and the “structural” water molecule bound inside the β4-β5 loop in FABPs in red. 
(C) Comparison of the open conformation (cartoon) and the SAXS envelope from T51P data (blue transparent 
surface) from two orientations. (D) Fluorescence spectra of DAUDA with 10 µM proteins. (E) LC-MS fatty acid 
analysis. All P2 variants prefer either palmitate (C16:0) or 18-carbon fatty acids (C18:0 and C18:1) Recombinant 
P2 carries more C18 than C16 fatty acids.
www.nature.com/scientificreports/
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to aggregate. P2wt and the I43N and I52T mutants all bound to membranes with affinities in the 2–6 µM range, 
irrespective of the lipid composition (Table 3). Despite similar apparent affinity, the kinetics of the wild-type 
and mutant proteins were different, and in fact, more of the mutant proteins eventually bound to the membrane, 
giving a continuous increase in response during the injection (Fig. 4A). This could be a sign of aggregation of 
the mutants onto the lipid bilayer after initial binding. P2wt, on the other hand, bound rapidly to the membrane, 
reaching a plateau by the end of the injection, and dissociated fast. All these features were similar between mem-
branes made of DMPC:DMPG and DOPC:DOPG. The result is an indication of possible membrane-induced 
aggregation of mutant P2 forms. The behaviour of the P2 mutants resembles somewhat the kinetics shown by 
another major myelin protein, MBP, which folds onto the membrane surface, forming an amorphous phase of 
protein, and dissociates very slowly23,24.
All mutants stack lipid membranes, but T51P is less active. In compact myelin, P2 is located in 
the cytoplasmic leaflet, interacting with two apposing membranes. An important feature of P2 is to bind lipid 
membranes and to stack them into multilayered systems. To test whether the mutant variants are able to attach 
lipid membranes together, we used a lipid vesicle aggregation assay and measured the increase in the turbidity of 
a lipid vesicle solution caused by P2. The results demonstrate that both Ile mutants can bind and stack lipid mem-
branes as efficiently as P2wt (Fig. 5A). However, T51P showed a reduced capability to stack lipid membranes; 
the turbidity of the vesicle-T51P mixture was approximately half of that of the other samples (Fig. 5A). With 
Figure 4. Membrane surface binding. (A) DMPC:DMPG (top) and DOPC:DOPG (bottom) sensorgrams with 
injection of 4 µM protein. (B) DMPC:DMPG (top) and DOPC:DOPG (bottom) fits for a protein titration.
P2 variant P2wt I43N I52T
Lipid DMPC:DMPG DOPC:DOPG DMPC:DMPG DOPC:DOPG DMPC:DMPG DOPC:DOPG
Two-state reaction 6.03 ± 1.05 2.44 ± 0.54 3.77 ± 0.11 3.48 ± 2.64 6.37 ± 1.01 2.53 ± 1.28
Sigmoidal model 4.78 ± 0.45 2.59 ± 0.62 3.25 ± 2.69 5.24 ± 1.22 0.95 ± 0.06 3.12 ± 0.65
Table 3. Membrane surface affinity of P2 deduced from SPR data. The values are apparent Kd in µM, based on 
two separate experiments.
www.nature.com/scientificreports/
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extended incubation, the Ile mutants slowly lost the turbidity, as opposed to P2wt, hinting at different stability 
of the proteolipid complex (Fig. 5B). We also visualised membrane stacks induced by P2 using transmission 
electron microscopy (TEM) and negative staining. In contrast to a control sample with only single unilamellar 
DMPC:DMPG vesicles (Fig. 5B), all P2 variants induced the formation of large clusters of multilamellar mem-
brane stacks (Fig. 5C–F).
Discussion
Recently, three P2 point mutations were shown to result in the most common heritable human peripheral neu-
ropathy, CMT. All P2 patient mutations trigger an autosomal dominant form of demyelinating CMT14–6. P2 
mutations are located near each other in the structure, in close proximity to the fatty acid binding pocket and 
the gap between the strands β4 and β5. Comparing the sequences of all 12 human FABPs, it can be seen that the 
mutated residues are conserved in most human FABPs, especially those with a collision-type ligand transfer 
mechanism10. Based on our work, all CMT1-associated P2 mutant forms maintain their overall fold in the crystal 
state, but their stability is significantly reduced, and fatty acid and lipid membrane binding altered, compared to 
P2wt.
Most forms of CMT1 are caused by duplication or mutation of the pmp22 gene, thought to lead to misfolding 
and aggregation of PMP22 in the ER of myelinating Schwann cells25. The three P2 mutations (I43N, T51P, and 
I52T) studied here increase the tendency of P2 to form insoluble aggregates, when expressed in E. coli. Even 
though the prokaryotic expression system differs from the natural environment inside human Schwann cells, it 
can provide relevant information when comparing disease-associated forms of human proteins.
The secondary structure content of T51P in solution was lower than for the other variants. All forms of P2 
showed conformational changes upon lipid vesicle binding. These changes, also seen before with P2wt10, may 
originate from the α-helical lid, which interacts with the head groups of lipids and may be partially buried inside 
the lipid membrane. The changes could also result from a membrane-induced opening of the β barrel, leading to 
possible ligand exchange with the membrane. The results indicate that all P2 variants interact with lipid mem-
branes, but as seen with SPR, the mutants are different in their respective lipid binding dynamics.
Figure 5. Membrane stacking by P2. (A) Top: end-point turbidity assay with all P2 variants. Bottom: time 
dependence of turbidity for P2wt and the Ile mutants. (B–F) Negatively stained TEM images of DMPC:DMPG 
vesicles (B) with P2wt (C) and mutants (D-I43N, E-T51P, F-I52T). Scale bar: 100 nm.
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Importantly, the thermal stability of all three CMT-linked P2 variants is dramatically reduced compared to 
P2wt. This finding supports the results from the solubility studies; reduced protein stability leads to partial or 
complete unfolding and the formation of protein aggregates. Overall, the T51P mutation has the most striking 
effect on the biophysical properties of P2. These results raise a question whether these mutants are able to fold 
properly in Schwann cells, or if the mutations lead to misfolding and protein accumulation.
The crystal structures of the disease-associated mutants are highly similar to P2wt, also regarding the fatty acid 
binding pocket9,10, and differences are limited to 1–2 hydrogen bonds near the mutation site. Nevertheless, the 
fatty acid binding properties of all mutants differ from those of P2wt. Based on fluorescent probe assays, all three 
mutants bind fatty acids more effectively than P2wt, and T51P causes the highest change in DAUDA fluorescence. 
As DAUDA has a fairly large and rigid dansyl group at one end of the molecule, these results may suggest that 
T51P favours larger ligands than P2wt; the result can also reflect the increased open/close dynamics of the T51P 
variant. Different kinds of kinetics may come to play when the fatty acid ligand is replaced in this experiment, 
including affinities towards various ligands and different conformational dynamics.
RMSF analysis of MD simulations demonstrates altered dynamic properties for all disease mutants. Fatty 
acid-bound T51P is clearly more dynamic than P2wt and the other two mutants, and liganded T51P has more 
water molecules inside the β barrel than other palmitate-bound P2 variants. This is presumably the consequence 
of an increased flexibility of the α-helical lid and the β barrel structure of T51P, which at least to some extent 
arises from the lack of proper hydrogen bonds in the β sheet β1-4 (Fig. 1). The opening of the β barrel observed 
in the MD simulations and in solution SAXS is expected to be thermodynamically realistic, since no main-chain 
hydrogen bonds of the barrel need to be broken for the opening to occur. It is likely that we are, indeed, observ-
ing a functional mechanism for FABP opening, in a process that is complementary with ligand exchange. Such 
a mechanism was suggested earlier26, but to our knowledge, it has not been observed for FABPs. It is obvious 
that several factors may affect such conformational changes, including the bound ligand, contact to a membrane 
surface, and the presence of mutations. The opening of the β barrel could also be linked to misfolding and/or 
increased β aggregation, as observed for the T51P mutant.
A similar functional opening of a β barrel on the side has been observed for the bacterial outer membrane 
integral membrane protein BamA27,28. The barrel opens into the membrane, and the opening is believed to facil-
itate ligand exchange, similarly to the mechanism proposed here for myelin P2 and the FABP family. In the case 
of BamA, hydrogen bonds exist between the β strands in the closed state28, while in P2, no direct main-chain 
hydrogen bonds are observed even when the gap is closed. Lateral opening of the structure could present a gen-
eral means of ligand exchange in β-barrel proteins.
The altered biochemical and dynamic properties of the α-helical lid, the β barrel, and the internal binding 
pocket of the P2 mutants may also affect the binding of other possible ligands, including cholesterol, which is 
bulkier than fatty acids. Cholesterol is highly abundant in myelin, and it has a rate-limiting role in myelin com-
paction and protein trafficking in Schwann cells29. Schwann cells are sensitive towards changes in the stoichi-
ometry of their membrane components; for proper myelin assembly and especially myelin maintenance, precise 
amounts of different lipids are required30. Thus, altered fatty acid binding profiles and kinetics of membrane 
binding by the P2 mutants may lead to critical defects in Schwann cells and myelin stability.
P2 is localised in compact myelin, and it spontaneously stacks lipid membranes31. SPR showed that the mutant 
proteins bound to membrane surfaces, but had kinetics distinct from the wild-type protein, possibly indicating 
membrane-induced aggregation. Also all disease-associated forms of P2 induce the stacking of lipid membranes, 
as seen using TEM. A lower efficiency of the mutants to induce stable lipid membrane stacking could have severe 
effects on myelin compaction and stability.
Genetic knockout studies revealed changes in the lipid profile of PNS myelin in P2-deficient mice11, which 
emphasises the contribution and importance of P2 to lipid homeostasis of PNS myelin. In addition, all three 
CMT1-linked patient mutations disrupt the multilayered structure of myelin4–6. The altered stability, dynamics, 
and fatty acid/lipid membrane binding of the disease-associated P2 protein variants may be involved in CMT1 
etiology and give rise to myelin defects, including abnormal myelin compaction and irregular myelin sheaths, in 
P2-linked CMT1 patients.
To conclude, we have carried out a detailed characterisation of CMT1-linked P2 mutant proteins and observed 
differences in their respective structures, functional properties, and dynamics. While the crystal structures of all 
variants are very similar, the mutant variants show clear structural changes in solution and simulations, as well as 
functional and stability deficits. The pathogenic point mutations drastically lower the stability of the mutant pro-
tein variants, which also have altered ligand- and membrane-binding properties. The mutations may also affect 
the functional dynamics of the FABP β barrel, whereby the observed opening of the gap between strands β4 and 
β5 may represent a general ligand entry mechanism in the protein family.
Methods
Mutagenesis, protein expression, and purification. Human P2 with an N-terminal His6 tag followed 
by a Tobacco Etch virus (TEV) protease cleavage site in the pTH27 vector9 was used as a template in mutagenesis 
to produce expression constructs with the c.T128A (p.I43N), c.C151A (p.T51P), and c.T155C (p.I52T) muta-
tions. Mutagenesis was carried out using the QuikChange Site-Directed Mutagenesis protocol, and all mutations 
were confirmed by DNA sequencing. Proteins were expressed in E. coli BL21 RIPL (DE3) cells in ZYM-5052 
autoinduction medium32 with 100 µg/ml carbenicillin and 34 µg/ml chloramphenicol at +18 °C for 66 h. Cells 
were harvested and suspended in lysis buffer (0.3 M NaCl, 10 mM imidazole, 50 mM HEPES pH 7.5). Cells were 
lysed by sonication, and insoluble material was pelleted by centrifugation (30000 g, 40 min, at +4 °C). The soluble 
fraction was then mixed with the HisPur Ni-NTA Resin (Thermo Fisher Scientific) at +4 °C for 1 h. The resin was 
washed twice with washing buffer (0.3 M NaCl, 40 mM imidazole, 50 mM HEPES pH 7.5) using centrifugation 
(500 g, 5 min, at +4 °C) and then transferred into a gravity-flow column and further washed with 50 ml of washing 
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buffer. P2 was eluted with elution buffer (500 mM imidazole, 0.3 M NaCl, 50 mM HEPES pH 7.5). To cleave 
the His6 tag, 33 nmol of recombinant TEV protease33 were added. Imidazole was removed by dialysis through 
6000–8000 MWCO dialysis tubing (SpectraPor) against 0.3 M NaCl, 1 mM DTT, 20 mM HEPES pH 7.5 at +4 °C 
for 16 h. Both TEV and the cleaved His6 tag were removed with reverse chromatography using HisPur Ni-NTA. 
Finally, P2 was purified with SEC using the dialysis buffer and a Superdex 75 pg 16/600 column (GE Healthcare) 
and concentrated with an Amicon Ultra 15, MWCO 10 kDa concentrator (Millipore). In T51P purification, all 
buffers, excluding the SEC buffer, also contained 10% glycerol to maintain the protein soluble during purification.
Protein crystallisation, data collection, and structure determination. P2 mutants were crystallised 
at +4 or +20 °C using the sitting drop vapour diffusion method, while the concentrations of the I43N, T51P, and 
I52T mutants were 8.5, 6.2, and 5.5 mg/ml, respectively. 0.3 M NaCl, 10% glycerol, 20 mM HEPES pH 7.5 was 
used as the protein buffer and 100 µl of 2.1 M DL-malic acid pH 7.25–7.5 as the reservoir solution, with 600-nl 
drops containing an equal volume of reservoir and protein. Diffraction data were collected at 100 K on beamline 
I03 and I04 at the Diamond Light Source, Didcot, UK, and processed using XDS34. The structures were solved 
by molecular replacement using the human P2 structure (PDB entry 4BVM10) as a search model in Phaser35. The 
structures were refined and built using phenix.refine36 and Coot37. The refined coordinates and structure factors 
were deposited at the PDB with the entry codes 5N4M (I43N), 5N4P (I52T), and 5N4Q (T51P).
Small-angle X-ray scattering. Synchrotron SAXS data were collected on beamline P12 at the PETRAIII 
storage ring, DESY, Hamburg, Germany. 0.6–4.1 mg/ml P2wt, I43N, and I52T were studied in a buffer containing 
0.3 M NaCl, 20 mM HEPES pH 7.5, and T51P in a buffer containing 0.3 M NaCl, 5% glycerol, 20 mM HEPES pH 
7.5. Data were processed and further analysed using the ATSAS program package38.
Protein aggregation analysis and dynamic light scattering. Samples from soluble and insoluble 
fractions were taken and run on SDS-PAGE. Intensities of the P2 protein bands were determined using ImageJ39. 
Soluble fractions were then calculated (%). DLS measurements were conducted as triplicates at +25 °C with 
protein concentrations of 0.6–0.9 mg/ml in a buffer containing 0.3 M NaCl, 20 mM HEPES pH 7.5, using the 
DynaPro Plate Reader II (Wyatt). After SEC, the proteins were stored on ice for 24 h before DLS measurements.
Circular dichroism spectroscopy. SRCD was carried out on the DISCO (SOLEIL synchrotron, Paris) and 
UV-CD12 (ANKA synchrotron, Karlsruhe) beamlines. Proteins were first dialysed into 10 mM sodium phosphate 
pH 7.5 or dH2O. SRCD spectra were measured at +30 °C using 0.2 mm pathlength quartz cuvettes with protein 
concentrations of 17–21 µM (~0.3 mg/ml). Spectra for the P2 variants were also recorded in the presence of unil-
amellar vesicles containing a 1:1 molar ratio of DMPC and DMPG, or DOPC and DOPG. The molar protein:lipid 
ratio was 1:100. Thermal stability measurements were carried out using a Chirascan Plus CD spectropolarimeter 
(Applied Photophysics). Proteins were first diluted into 10 mM sodium phosphate buffer (pH 7.5) to final con-
centrations of 3.4 µM (50 µg/ml). CD spectra were then recorded at 195–260 nm with a ramping rate of 1 °C/min 
between +22–90 °C. The melting temperatures (Tm) were calculated using Global 3 (Applied Photophysics).
Atomistic molecular dynamics simulations. The protein with bound palmitate was obtained from the 
PDB entry 4BVM10 and converted to the CHARMM36 force field40. The topology for P2wt was directly obtained 
from the conversion. The point mutations (I43N, T51P, and I52T) were constructed from P2wt. Water molecules 
were modeled using the TIP3P model41.
Eight different systems were studied: P2wt and its point-mutated forms I43N, T51P, and I52T, all with and 
without a bound palmitate molecule inside the binding pocket. The proteins were simulated in solvated cubic 
simulation boxes with sizes of approximately 8 × 8 × 8 nm3 and with 16000 water molecules, in accordance to 
our previous study42. Counter-ions (11 Cl− in palmitate-free proteins and 10 Cl− in proteins with palmitate) were 
included to neutralise the total charge of the system.
The MD simulations were carried out under NpT conditions. Temperatures were coupled using the 
velocity-rescale (v-rescale) method, with separate temperature coupling for protein and solvent. Reference tem-
peratures of 300 K were used with coupling time constants of 2.0 ps. Pressure coupling was done isotropically 
with the isothermal Parrinello-Rahman barostat43 at a reference pressure of 1 bar with a coupling time constant of 
2.0 ps and isothermal compressibility of 4.5 × 10−5 bar−1. All bonds were constrained with the LINCS algorithm44. 
Periodic boundary conditions were used. A cut-off radius of 1.0 nm was introduced for the neighbor list, the 
Lennard-Jones interactions, and the non-bonded interactions. The particle-mesh Ewald (PME) method45 with 
cubic interpolation was used for calculating long-range electrostatics, using a spacing of 0.16 nm for the Fourier 
grid.
All simulations were conducted using GROMACS 4.6.746. A time step of 2 fs was used in integrating the equa-
tions of motion. All systems were first energy-minimised with the steepest descent algorithm and then simulated 
for a total of 2.5 µs each. An equilibration period of 500 ns was removed from the beginning of each trajectory, 
using the final 2 µs for analysis. The trajectory coordinates were saved every 50 ps.
The RMSF was calculated for each residue using the GROMACS tool g_rmsf. The RMSF of a residue shows its 
stability; the larger the value, the more mobile it is. Therefore, by calculating the RMSF, we can determine, which 
parts of the protein are most affected by the mutation and/or the presence of the ligand. Water analysis was done 
with the GROMACS tool trjorder by calculating the number of water molecules within 0.9 nm of the center of 
mass of the protein backbone (the radius of the P2 barrel is about 1.0 nm) at every time step over the course of 
the simulation.
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Fatty acid binding assay. Fatty acid binding to P2 was studied with a fluorescent fatty acid analog, 
DAUDA. 10 µM DAUDA and 10 µM P2 were incubated for 1 h in 150 mM NaCl, 10 mM HEPES pH 7.5 at +23 °C. 
Fluorescence emission spectra were recorded with excitation at 345 nm and emission between 400–700 nm, using 
a Tecan Infinite M1000Pro plate reader.
Liquid chromatography-mass spectrometry for fatty acids. 20-µl aliquots of protein solutions 
adjusted to the same concentration (30 µM; 0.45 mg/ml) were acidified with 1 µl formic acid and then precipitated 
with 20 µl of acetone. Samples came from 2–3 separate production batches for each variant, and each sample 
was analysed 1–2 times. After centrifugation, fatty acids were extracted into 20 µl of chloroform, the phases were 
separated by short centrifugation, and 5 µl of the chloroform phase was subjected to LC-MS using an Acquity 
UPLC system coupled to a SynaptG1 Q-TOF type mass spectrometer. The chromatography column was a BEH 
C18, 2.1 × 100, eluted with a gradient of acetonitrile (A: acetonitrile, B: 10 mM ammonium acetate 10% A to 
100% A in 8 min, flow 0.3 ml/min). The mass spectrometer was operated in negative mode, collecting 0.2-s scans 
in centroid mode from m/z 50 to 1000. LC-MS was performed at the Proteomics and protein analysis core facility 
of Biocenter Oulu.
Surface plasmon resonance. SPR assays were performed using BiacoreT200 (GE Healtcare) for P2wt as 
well as the I43N and I52T mutants. Due to its low stability and tendency to aggregate, T51P was not used in SPR. 
1 mM DOPC:DOPG (1:1) and DMPC:DMPG (1:1) vesicles in a buffer containing 150 mM NaCl and 10 mM 
HEPES pH 7.5 were immobilised on an L1 sensor chip (GE Healthcare) according to the manufacturer’s instruc-
tions. The surface was then saturated with an injection of 1 µM bovine serum albumin (BSA). Lipid immobilisa-
tion and BSA injection were done for each SPR cycle. Duplicate injections of P2wt and the mutants at 0.1–10 µM, 
using 150 mM NaCl, 10 mM HEPES pH 7.5 as the running buffer, were carried out at +30 °C. Results were ana-
lysed with BiaEvaluation (GE Heathcare) using a kinetic two-state binding model as well as steady-state affinity. 




x x b(1 exp( ( )/ )) (1)0 0
in SigmaPlot.
Vesicle binding assays. For a single-point assay, 0–10 µM P2 was mixed with 0.5 mM unilamellar vesicles 
containing a 1:1 molar ratio of DMPC:DMPG in 150 mM NaCl, 10 mM HEPES pH 7.5, and the samples were 
incubated for 35 min at +30 °C. The turbidity of the vesicle-protein solutions was measured with a Tecan Infinite 
M1000 Pro plate reader using absorbance at 450 nm at +30 °C. The assay was repeated 3–5 times with all concen-
trations and P2 forms.
In order to study the time course of vesicle aggregation, 0.5 mM DMPC:DMPG vesicles were mixed with 5 µM 
P2 in buffer containing 150 mM NaCl and 10 mM HEPES (pH 7.5). A VersaMax microplate reader (Molecular 
Devices) was used to measure the turbidity at 1-min intervals, shaking before each measurement. The tempera-
ture was set at +30 °C and the wavelength at 460 nm. The difference of 10 nm in the wavelength in the above two 
experiments was not considered to affect the outcome, as the measurement follows turbidity of the sample.
Transmission electron microscopy. 34 µM (0.5 mg/ml) P2 was mixed with 740 µM (0.5 mg/ml) 
DMPC:DMPG (1:1) unilamellar vesicles, and the samples were incubated at +22 °C for 1 h. 4-µl samples were 
then pipetted onto glow-discharged carbon-coated copper grids, and after incubating for 1 min, excess solution 
was removed with filter paper. After 4 washes in droplets of dH2O, samples were negatively stained with two 
drops of 2% uranyl acetate for 12 s in each drop and air-dried. TEM images were recorded using a Tecnai G2 Spirit 
120 kV instrument equipped with a Quamesa CCD camera (Olympus Soft Imaging Solutions) at the EM core 
facility of Biocenter Oulu.
Data availability. The crystal structure coordinates and structure factors are available at the PDB with the 
entry codes 5N4M (I43N), 5N4P (I52T), and 5N4Q (T51P). Other datasets analysed during the current study are 
available from the corresponding author upon reasonable request.
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